A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial) | Zendy

Mitchell Nides | Zendy; Nancy A. Rigotti | Zendy; Neal L. Benowitz | Zendy; Anthony Clarke | Zendy; Cindy Jacobs | Zendy

Open Access

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial)

Author(s) -

Mitchell Nides,

Nancy A. Rigotti,

Neal L. Benowitz,

Anthony Clarke,

Cindy Jacobs

Publication year - 2021

Publication title -

nicotine and tobacco research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.338

H-Index - 113

eISSN - 1469-994X

pISSN - 1462-2203

DOI - 10.1093/ntr/ntab073

Subject(s) - placebo , abstinence , tolerability , medicine , smoking cessation , randomized controlled trial , anesthesia , placebo controlled study , adverse effect , double blind , psychiatry , alternative medicine , pathology

Cytisinicline (known as cytisine), a nicotinic acetylcholine receptor partial agonist, is a smoking cessation aid currently marketed in Central and Eastern Europe using a 1.5-mg/tablet 25-day downward titration schedule. No prior studies have evaluated other doses or administration schedules. This study evaluated the effects of a higher dosage and simplified dosing schedule on drug efficacy and tolerability.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research